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Abstract
Defects in apoptosis contribute to treatment resistance and poor outcome of pancreatic cancer, calling for novel
therapeutic strategies. Here, we provide the first evidence that nuclear factor (NF) κB is required for Smac mimetic–
mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. The Smac mimetic BV6
cooperates with gemcitabine to reduce cell viability and to induce apoptosis. In addition, BV6 significantly enhances
the cytotoxicity of several anticancer drugs against pancreatic carcinoma cells, including doxorubicin, cisplatin, and
5-fluorouracil. Molecular studies reveal that BV6 stimulates NF-κB activation, which is further increased in the pres-
ence of gemcitabine. Importantly, inhibition of NF-κB by overexpression of the dominant-negative IκBα superrepressor
significantly decreases BV6- and gemcitabine-induced apoptosis, demonstrating that NF-κB exerts a proapoptotic
function in this model of apoptosis. In support of this notion, inhibition of tumor necrosis factor α (TNFα) by the TNFα
blocking antibody Enbrel reduces BV6- and gemcitabine-induced activation of caspase 8 and 3, loss of mitochondrial
membrane potential, and apoptosis. By demonstrating that BV6 and gemcitabine trigger a NF-κB–dependent, TNFα-
mediated loop to activate apoptosis signaling pathways and caspase-dependent apoptotic cell death, our findings
have important implications for the development of Smac mimetic–based combination protocols in the treatment
of pancreatic cancer.
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Introduction
Pancreatic cancer belongs to the leading causes of cancer deaths in the
Western world [1]. Treatment resistance of pancreatic cancer, for
example, to chemotherapy, remains a major challenge in oncology,
and this can be caused by evasion of apoptosis—the cell’s intrinsic
cell death program [2]. This highlights the need for novel strategies
to overcome apoptosis resistance in pancreatic cancer.
Apoptosis signaling pathways operate through two major routes, i.e.,
through the death receptor (extrinsic) pathway and through the mito-
chondrial (intrinsic) pathway, which result in activation of caspases as
common effector molecules of cell death [3]. Activation of receptors of
the tumor necrosis factor (TNF) receptor superfamily, for example,
TNF-related apoptosis-inducing ligand (TRAIL) receptors or TNF
receptor 1 (TNFR1), results in activation of the initiator caspase 8,
which in turn activates effector caspases such as caspase 3 [4]. The
intrinsic (mitochondrial) pathway involves the permeabilization of
the outer mitochondrial membrane and the release of mitochondrial
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intermembrane space proteins such as cytochrome c and second
mitochondria-derived activator of caspase (Smac)/direct inhibitor of
apoptosis (IAP) binding protein with low pI into the cytosol [5].
Cytochrome c triggers caspase 3 activation through the apoptosome
complex, whereas Smac promotes caspase 3 activation by binding to
and neutralizing X-linked IAP (XIAP) [5].
IAP proteins comprise eight individual members that all harbor a
baculovirus IAP repeat (BIR) domain [6]. In addition, XIAP, cellular
IAP 1 (cIAP1), and cIAP2 harbor a RING domain with E3 ubiquitin
ligase activity, which mediates (auto)ubiquitination and proteasomal
degradation [6]. XIAP is best characterized for its antiapoptotic func-
tion by binding to and inhibiting caspase 9 and caspase 3/7 through
its BIR3 domain and the linker region preceding BIR2 domain, respec-
tively [6]. Recently, cIAP1 and cIAP2 were identified as E3 ubiquitin
ligases for the serine/threonine kinase RIP1 that put K63-linked
ubiquitin chains on RIP1 [7,8]. Furthermore, a cIAP-TRAF destruc-
tion complex keeps the basal level of NIK low and is involved in reg-
ulating noncanonical NF-κB signaling [6]. In addition to neutralizing
the inhibitory function of XIAP on caspase activation, Smac mimetics
have been shown to trigger autoubiquitination and proteasomal deg-
radation of IAP proteins with a RING domain, thereby promoting
NF-κB activation and TNFα-dependent cell death [9–11].
The transcription factor NF-κB functions as a dimer that is com-
posed of proteins of the NF-κB/Rel family [12]. On stimulation, the
IκB kinase complex becomes activated, which initiates the proteasomal
degradation of IκBα, which in turn releases NF-κB to translocate to the
nucleus [12]. NF-κB is usually considered to negatively regulate apop-
tosis, for example, through transcriptional activation of antiapoptotic
proteins [12].
We previously reported that inhibition of XIAP profoundly en-
hances TRAIL-induced apoptosis in pancreatic carcinoma in vitro
and in vivo [13–15]. Searching for novel strategies to enhance chemo-
sensitivity of pancreatic cancer, we investigated the effect of a small
molecule Smac mimetic on anticancer drug–induced apoptosis in
the present study.
Materials and Methods
Cell Culture and Reagents
Pancreatic carcinoma cells were cultured in Dulbecco modified
Eagle medium (Life Technologies, Inc, Eggenstein, Germany) sup-
plemented with 10% fetal calf serum (Biochrom, Berlin, Germany),
1 mM glutamine (Biochrom), 1% penicillin/streptavidin (Biochrom),
and 25 mMHEPES (Biochrom) as described [15]. The bivalent Smac
mimetic BV6 has previously been characterized, and the structure
of the compound (Figure W1) has previously been published [10].
Gemcitabine was obtained from Lilly (Bad Homburg, Germany);
doxorubicin, etoposide, and cisplatin were obtained from Sigma (Steinheim,
Germany); N -benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
(zVAD.fmk) was obtained from Bachem (Heidelberg, Germany);
Enbrel was obtained from Pfizer (New York, NY); and necrostatin-1
was obtained from Biomol (Hamburg, Germany). All chemicals were
purchased from Sigma unless indicated otherwise.
Determination of Apoptosis and Cell Viability
Apoptosis was determined by fluorescence-activated cell-sorting
analysis (FACScan; BD Biosciences, Heidelberg, Germany) of DNA
fragmentation of propidium iodide–stained nuclei as previously de-
scribed [16]. Cell viability was assessed by MTT assay according to the
manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany).
Western Blot Analysis
Western blot analysis was performed as described [15] using the
following antibodies: mouse anti–caspase 8 (ApoTech Corporation,
Epalinges, Switzerland), rabbit anti–caspase 3 (Cell Signaling, Beverly,
MA), mouse anti-XIAP, mouse anti–Bcl-XL from BD Biosciences,
rabbit anti-cIAP2 (Epitomics, Burlingame, CA), goat anti-cIAP1 and
rabbit anti-survivin (R&D Systems, Inc, Wiesbaden, Germany), rabbit
anti-IκBα (Santa Cruz Biotechnology, Santa Cruz, CA), or mouse
anti–β-actin (Sigma) followed by goat-antimouse IgG or goat-antirabbit
IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology).
Enhanced chemiluminescence was used for detection (Amersham Bio-
science, Freiburg, Germany).
Determination of Mitochondrial Membrane Potential
and Cytochrome c Release
For determination of mitochondrial transmembrane, potential cells
were incubated with tetramethylrhodamine methylester perchlorate
(0.2 μg/ml; Sigma) for 10 minutes at 37°C and immediately analyzed
by flow cytometry.
Retroviral Transduction
Overexpression of the dominant-negative IκBα superrepressor was
performed by retroviral transduction using IκBα (S32; 36A) and the
pCFG5-IEGZ retroviral vector system as previously described [17].
In brief, stable PT67 producer cells (Clontech, Palo Alto, CA) were
transfected with empty pCFG5-IEGZ vectors or pCFG5-IEGZ vectors
containing IκBα (S32; 36A) using Lipofectamine 2000 (Invitrogen,
Karlsruhe, Germany) according to the manufacturer’s recommendation
and selected with 0.25 mg/ml Zeocin (InvivoGen, San Diego, CA).
Stable Panc1 cells were obtained by retroviral spin transduction and
subsequent selection with Zeozin.
Nuclear Protein Extraction and Electrophoretic Mobility
Shift Assay
Nuclear extracts were prepared as previously described [18]. In brief,
cells were washed, scraped, and collected by centrifugation at 1000g for
5 minutes at 4°C. Cells were resuspended in low-salt buffer and allowed
to swell on ice for 12 minutes; a 10% Igepal CA-630 (Sigma-Aldrich)
solution was added and after vortexing the cell suspension was centri-
fuged again. The pelleted nuclei were resuspended in high-salt buffer,
incubated on ice, and vortexed at times for 20 minutes. Nuclear super-
natants were obtained by centrifugation at 12,500g at 4°C for 12 minutes.
Protein concentrations were determined using the BCA Protein assay Kit
(Pierce, Rockford, IL). For electrophoretic mobility shift assay (EMSA),
the following sequence was used as specific oligomer for NF-κB: 5′-
AGTTGAGGGGACTTTCCCAGGC-3′ (sense). Single-stranded oligo-
nucleotides were labeled with γ-[32P]-ATP by T4-polynucleotide kinase
(MBI Fermentas GmbH, St. Leon-Rot, Germany), annealed to the com-
plementary oligomer strand, and purified on sephadex columns (Micro
Bio-Spin P30; Bio-Rad Laboratories, Munich, Germany). Binding re-
actions containing 5 μg of nuclear extract, 1 μg of poly(dI:dC) (Sigma),
labeled oligonucleotide (10,000 cpm), and 5× binding buffer were
incubated for 30 minutes on ice. Binding complexes were resolved by
electrophoresis in nondenaturing 6% polyacrylamide gels using 0.3×
TBE as running buffer and assessed by autoradiography. Representative
EMSAs are shown.
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Luciferase Assay
The Dual-Luciferase Reporter Assay System (Promega, Madison,
WI) was used to determine firefly and Renilla luciferase activities as
previously described [18] using 3× κB-firefly luciferase vector contain-
ing 3× κB consensus motif (CCCTGAAAGG) or a Renilla luciferase
vector under the control of the ubiquitin promoter. Firefly luciferase
values were normalized to Renilla luciferase values.
EMSA
EMSA was performed with IRDye-labeled double-stranded oligo-
nucleotides containing a NF-κB consensus site (5′-AGTTGAGGG-
GACTTTCCCAGGC-3′) or NF-κB mutated site (5′-AGTTGAAT-
TCACTTTCCCAGGC-3′) using the Odyssey infrared imaging system
(LI-COR, Bad Homburg, Germany) according to the instructions of
the manufacturer. The DNA binding reactions were set up by incubating
Figure 1. BV6 enhanced gemcitabine-induced loss of viability. Panc1 (left) and MiaPaCa2 (right) cells were treated with indicated con-
centrations of gemcitabine (A), etoposide (B), doxorubicin (C), and cisplatin (D) and/or 2 μM BV6 for 72 hours. Cell viability was assessed
by MTT assay and is calculated as percentage of untreated cells. Means ± SEM of three independent experiments performed in triplicate
are shown. *P < .01 comparing samples in the presence or absence of BV6.
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15 μg of nuclear proteins and 125 fmol of oligonucleotides in the dark for
30 minutes at room temperature in 20 μl of binding buffer (20% glycerol,
5 mM MgCl2, 2.5 mM EDTA, 2.5 mM dithiothreitol, 250 mM
NaCl, 50 mM Tris-HCl, pH 7.5, 0.25 mg/ml polydeoxyinosinic-
polydeoxycytidylic acid). The reaction mixture was run on a 5% PAGE
gel in high ionic strength buffer (0.05 M Tris, pH 8.5, 380 mM glycine,
2 mM EDTA). Gels were recorded using the Odyssey infrared imaging
system (LI-COR). Binding of labeled oligonucleotides was shown to be
sequence-specific by demonstrating that binding was blocked by an
excess (250 fmol) of unlabeled oligonucleotides.
Cell Cycle Analysis
Cell cycle analysis was performed by propidium iodide staining of per-
meabilized cells and flow cytometry (FACSCanto II; Becton Dickinson,
Heidelberg, Germany). A total of 10,000 events were counted for each
sample. Data were analyzed with FlowJo software (Celeza GmbH,
Olten, Switzerland) choosing the Dean-Jet-Fox model analysis.
Determination of TNFα Secretion
TNFα levels in cell supernatants were determined by ELISA (BD
Biosciences) according to the manufacturer’s instructions.
Statistical Analysis
Statistical significance was assessed by two-sided Student’s
t test using Microsoft Excel (Microsoft Deutschland GmbH,
Unterschleißheim, Germany).
Results
BV6 Promotes Chemotherapy-Induced Apoptosis
To investigate whether the bivalent Smac mimetic BV6 alters
chemosensitivity of pancreatic carcinoma cells, we analyzed the effect
of several chemotherapeutic drugs on cell viability in the presence and
absence of BV6. For these experiments, we chose a concentration of
Figure 2. BV6 enhances gemcitabine-induced apoptosis. (A) DNA fragmentation. Panc1 (left) and MiaPaCa2 (right) cells were treated
with indicated concentrations of gemcitabine and/or 2 μMBV6 for 72 hours. Apoptosis was determined by FACS analysis of DNA fragmen-
tation of propidium iodide–stained nuclei. Means ± SEM of three independent experiments performed in triplicate are shown. *P < .01
comparing samples in the presence or absence of BV6. (B) Caspase cleavage. Panc1 (left) andMiaPaCa2 (right) cells were treated with 100 nM
(Panc1) or 66 nM (MiaPaCa2) gemcitabine and/or 2 μMBV6 for indicated time points. Cleavage of caspase 8 and 3was assessed byWestern
blot analysis. β-Actin served as loading control. One representative Western blot of two independent experiments is shown.
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BV6 that exerted limited cytotoxicity as single agent (Figure W2A).
Importantly, the addition of BV6 significantly decreased viability in
a dose-dependent manner on treatment of Panc1 and MiaPaCa2 pan-
creatic carcinoma cells with several different cytotoxic drugs, namely,
gemcitabine, doxorubicin, cisplatin, and 5-fluorouracil, compared to
treatment with either drug alone (Figure 1). Kinetic studies demon-
strated the time dependency of the BV6-mediated sensitization
(Figure W2B). This shows that the Smac mimetic BV6 sensitizes pan-
creatic carcinoma cells toward chemotherapy.
Since gemcitabine is the first-line chemotherapeutic agent that is
used in the clinic for the treatment of pancreatic cancer, we focused
subsequent experiments on this cytotoxic drug. To explore whether
loss of viability was due to the induction of apoptosis, we determined
DNA fragmentation as a characteristic marker of apoptosis. BV6 sig-
nificantly enhanced gemcitabine-induced apoptosis as assessed by
DNA fragmentation in a dose-dependent manner (Figure 2A). As
an additional parameter of apoptotic cell death, we monitored caspase
activation by Western blot analysis. Combination treatment with BV6
and gemcitabine resulted in enhanced cleavage of caspase 3 and 8 into
active fragments compared to either single-agent treatment alone as
evident from the increased processing of caspase 8 to the p43/p41
and p18 fragments and of caspase 3 to the p17/p12 active fragments
Figure 3. BV6- and gemcitabine-induced apoptosis is caspase- and TNFα-dependent. (A, B) Panc1 cells were treated for 72 hours with
100 nM gemcitabine and/or 2 μM BV6 and/or 20 μM zVAD.fmk, 30 μM necrostatin 1, 5 μg/ml Enbrel. Cell viability was assessed by MTT
assay (A). Apoptosis was determined by FACS analysis of DNA fragmentation of propidium iodide–stained nuclei (B). Means ± SEM of
three independent experiments performed in triplicate are shown. *P < .01. (C) Panc1 cells were treated for 48 hours with 100 nM
gemcitabine and/or 2 μM BV6. TNFα protein levels in supernatants were determined by ELISA, and fold increase in TNFα secretion
relative to untreated control is shown. Means ± SD of three experiments performed in triplicate are shown. *P < .05 comparing
BV6 treatment to untreated control. (D) Panc1 cells were treated 100 nM gemcitabine and/or 2 μM BV6 in the presence or absence
of 5 μg/ml Enbrel for 48 hours. Cleavage of caspase 8 and 3 was assessed by Western blot analysis. One representative of two experi-
ments is shown. (E) Panc1 cells were treated with 100 nM gemcitabine and/or 2 μM BV6 in the presence or absence of 5 μg/ml Enbrel
for 48 hours. Loss of mitochondrial membrane potential (MMP) was assessed by flow cytometry. Means ± SEM of three independent
experiments performed in triplicate are shown. *P < .01.
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(Figure 2B). Together, these results demonstrate that BV6 increases
gemcitabine-induced caspase activation and apoptosis in pancreatic
carcinoma cells.
Requirement of Caspases and TNFα for BV6- and
Gemcitabine-Induced Apoptosis
To gain insight into the pathways involved in the BV6-mediated
sensitization to gemcitabine, we analyzed the effect of BV6 on ex-
pression of IAP proteins. Treatment with BV6 caused rapid down-
regulation of cIAP1 and cIAP2 (Figure W3). Also, the expression of
XIAP was reduced on longer treatment with BV6 (MiaPaCa2) or the
combination of BV6 and gemcitabine (Panc1 and MiaPaCa2;
Figure W4). These findings are consistent with the reported protea-
somal degradation of IAP proteins on treatment with Smac mimetics
such as BV6 [10]. By comparison, the addition of BV6 did not alter
gemcitabine-induced cell cycle changes (Figure W4).
Next, we tested the effect of different pharmacological inhibitors that
interfere with individual pathways. The addition of the broad-range
caspase inhibitor zVAD.fmk significantly rescued loss of viability and
induction of apoptosis on the combination treatment with BV6 and
gemcitabine (Figure 3, A and B), thus pointing to caspase-dependent
cell death.
In addition, we tested the involvement of RIP1 and TNFα, which
have been implicated in BV6-induced cell death [7,9–11,19]. Treatment
with necrostatin 1, a RIP1-specific inhibitor [20], had no effect on BV6-
and gemcitabine-induced loss of viability or induction of apoptosis
(Figure 3, A and B). Of note, the TNFα antagonistic antibody Enbrel
significantly reduced loss of viability and apoptosis induction on the
combination treatment with BV6 and gemcitabine (Figure 3, A and
B). To determine whether BV6 triggers TNFα release, we assessed
TNFα in the supernatant. Indeed, treatment with BV6 or BV6 plus
gemcitabine stimulated TNFα release (Figure 3C). This indicates that
TNFα is involved in mediating BV6- and gemcitabine-induced cell
death in an autocrine/paracine manner. The combined use of zVAD.
fmk together with TNFα or necrostatin 1 did not augment the protec-
tive effect of zVAD.fmk alone (Figure 3, A and B), further supporting
the notion that cell death occurs in a caspase-dependent manner.
Since TNF receptor activation after binding of TNFα can initiate
both survival and cell death pathways, we next assessed the effect of
Enbrel on the extrinsic and intrinsic apoptosis signaling pathways on
treatment with BV6 and/or gemcitabine. For the extrinsic apoptosis
pathway, we monitored activation of the caspase cascade. Importantly,
cleavage of the initiator caspase 8 into active fragments after treatment
with BV6 or BV6 plus gemcitabine was profoundly inhibited in the
presence of Enbrel (Figure 3D). Similarly, Enbrel inhibited BV6- and
gemcitabine-induced processing of the effector caspase 3 into active frag-
ments (Figure 3D). We also explored whether activation of the intrinsic
pathway was regulated by TNFα. Of note, Enbrel significantly reduced
loss of mitochondrial membrane potential on treatment with BV6 as
single agent and in combination with gemcitabine (Figure 3E). Together,
this set of experiments suggests that TNFα mediates at least in part
BV6- and gemcitabine-induced cell death.
NF-κB Promotes BV6- and Gemcitabine-Induced Apoptosis
As Smac mimetic–induced NF-κB activation has been reported to
stimulate TNFα production [9–11], we next analyzed NF-κB DNA
binding activity by EMSA. Treatment with BV6 stimulated NF-κB
DNA binding, which was further increased transiently after the addi-
tion of gemcitabine for 4 hours (Figure 4A). By comparison, treatment
with gemcitabine alone for up to 48 hours did not substantially alter
NF-κB DNA binding (Figure 4A and data not shown). Stimulation
with TNFα in the presence or absence of cold or mutated oligonucleotides
was used as control for NF-κB activation (Figure W5). NF-κB transcrip-
tional activation was confirmed by luciferase reporter assay (Figure 4B).
To explore whether NF-κB activation results in up-regulation of anti-
apoptotic genes, we performed Western blot analysis. Treatment with
BV6-triggered down-regulation of cIAP1 and cIAP2 (Figure W3)
was consistent with Smac mimetic–stimulated proteasomal degrada-
tion of IAP proteins [10], whereas it caused a slight increase in Bcl-XL
expression (Figure 4C).
To explore whether NF-κB inhibits or promotes cell death in this
model of apoptosis, we blocked NF-κB translocation to the nucleus
and subsequent NF-κB activation by overexpression of IκBα super-
repressor (IκBα-SR), a dominant-negative form of IκBα that cannot
be phosphorylated and degraded due to two point mutations. Con-
trol experiments demonstrated that IκBα-SR protein is expressed and
inhibits NF-κB DNA binding on stimulation with TNFα, which
Figure 4. NF-κB activation by BV6. (A) Panc1 cells were treated
with 100 nM gemcitabine and/or 2 μM BV6 for 4 or 24 hours. Stim-
ulation with 10 ng/ml TNFα for 1 hour served as positive control.
NF-κB activation was assessed by the analysis of NF-κB DNA bind-
ing by EMSA. One representative of three experiments is shown.
(B) Panc1 cells were transiently transfected with firefly and Renilla
luciferase gene constructs, treated with 100 nM gemcitabine and/or
2 μM BV6 for 24 hours, and analyzed by dual luciferase assay for
induction of NF-κB transcriptional activity. Fold increase in luciferase
activity relative to untreated control is shown. Means ± SD of three
experiments performed in triplicate are shown. *P < .05 comparing
BV6 treatment to untreated control. (C) Panc1 cells were treated
with 100 nM gemcitabine and/or 2 μM BV6 for 24 hours. Protein ex-
pression of Bcl-XL was assessed by Western blot analysis. β-Actin
served as loading control.
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was used as a prototypic activator of NF-κB, or on stimulation with
BV6 and/or gemcitabine (Figures 5, A and B, and W6). Importantly,
inhibition of NF-κB profoundly inhibited loss of viability on treatment
with BV6 and gemcitabine (Figure 5C). Similarly, NF-κB inhibition
significantly reduced BV6- and BV6/gemcitabine–induced apoptosis
(Figure 5D). These results demonstrate that NF-κB is critical for
BV6- and gemcitabine-induced apoptosis.
Discussion
Pancreatic carcinoma represents a prototypic apoptosis-resistant
cancer [2] calling for new concepts to activate the apoptotic machinery.
In the present study, we provide the first evidence that the Smac
mimetic BV6 sensitizes pancreatic carcinoma cells for gemcitabine-
induced apoptosis in a NF-κB–dependent manner. The following
independent pieces of evidence support this conclusion: First, BV6
primes pancreatic carcinoma cells for gemcitabine-mediated apoptosis
and also significantly enhances the cytotoxicity of several anticancer
drugs, including doxorubicin, cisplatin, and 5-fluorouracil. Second,
inhibition of caspases by the broad-range inhibitor zVAD.fmk pro-
foundly inhibits BV6- and gemcitabine-induced apoptosis, demon-
strating that cell death occurs in a caspase-dependent manner. Third,
BV6 stimulates NF-κB activation, which is further increased in the
presence of gemcitabine. Fourth, inhibition of NF-κB by overexpression
of the dominant-negative IκBα-SR significantly decreases BV6- and
Figure 5. Requirement of NF-κB for BV6- and gemcitabine-induced cell death. Panc1 cells were stably transducedwith a vector containing
IκBα-SR or empty control vector. (A) Expression of IκBα-SR was determined byWestern blot analysis using. (B) NF-κB activation in control
and IκBα-SR–overexpressing cells was determined by EMSA after stimulation with 10 ng/ml TNFα for 1 hour. (C) IκBα-SR–overexpressing
and control cells were treated with 2 μM BV6 and/or indicated concentrations of gemcitabine (nM) for 72 hours. Cell viability was deter-
mined by MTT assay, and this is calculated as the percentage of untreated cells. Means ± SEM of three independent experiments per-
formed in triplicate are shown. *P < .01.
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gemcitabine-induced apoptosis, pointing to a proapoptotic function of
NF-κB in this model of apoptosis. Fifth, inhibition of TNFα by the
TNFα blocking antibody Enbrel reduces activation of caspase 8 and 3,
mitochondrial perturbation and apoptosis. These findings are consistent
with a model that BV6 and gemcitabine trigger a NF-κB–dependent,
TNFα-mediated loop to activate apoptosis signaling pathways and
caspase-dependent apoptotic cell death.
Compared with our previous studies on the synergistic interaction
of small molecule IAP inhibitors and the death receptor ligand
TRAIL in pancreatic carcinoma [13,14,21], the novelty of the current
report in particular resides in the demonstration that NF-κB is criti-
cally required for the BV6-mediated sensitization for gemcitabine-
induced apoptosis. The proapoptotic function of NF-κB during
apoptosis on treatment with BV6 alone or the combination of BV6
plus gemcitabine may be explained by the BV6-conferred switch of
the TNFα response from survival to cell death through BV6-triggered
degradation of cIAP1. Accordingly, Smac mimetics have been shown
to interfere with cIAP-mediated ubiquitination of RIP1 by stimulat-
ing degradation of cIAPs, which favors the formation of the RIP1/
FADD/caspase 8 death complex on stimulation of TNFR1 [7]. Con-
sistently, we found that BV6- and gemcitabine-induced caspase activa-
tion, loss of mitochondrial membrane potential, and apoptosis occur in
a TNFα-dependent manner because addition of the TNFα blocking
antibody Enbrel inhibits all these events.
The identified proapoptotic function of NF-κB in the context of
BV6- and chemotherapy-mediated apoptosis in pancreatic cancer
cells is particularly noteworthy in light of the described antiapoptotic
role of NF-κB in this type of cancer. To this end, NF-κB activation
has been reported to prevent apoptosis in pancreatic carcinogenesis
[22] and to confer resistance of pancreatic carcinoma cells against
anticancer drug–induced cell death [23]. As far as apoptosis induced
by single-agent treatment with different forms of Smac mimetics is
concerned, NF-κB has been shown either to promote or to prevent cell
death induction in different cancer cell lines. Whereas NF-κB inhibition
was shown to potentiate Smac mimetic–triggered cytotoxicity in lung or
prostate carcinoma cells [24,25], Vince et al. [9] reported that blocking
NF-κB reduces Smacmimetic–mediated cell death in ovarian carcinoma
and rhabdomyosarcoma cells. These findings point to a context-
dependent role of NF-κB in Smac mimetic–induced cell death.
Furthermore, our study is the first to demonstrate that NF-κB is
required for cell death induction after treatment with the combina-
tion of BV6 and gemcitabine. By comparison, TNFα has been impli-
cated to mediate cell death induced by a Smac mimetic in combination
with chemotherapeutics [26,27]. Our findings underscore that NF-κB
may exert a tumor suppressor function under certain circumstances
and raise a cautious note on the use of NF-κB inhibitors in pancreatic
cancers in the context of Smac mimetics.
Our results have important implications for the future development
of Smac mimetic–based combination protocols for the treatment of
pancreatic cancer. Since the addition of BV6 markedly potentiates
the antitumor activity of several cytotoxic drugs against pancreatic
carcinoma cells, the incorporation of Smac mimetic into chemotherapy
protocols can be considered as a promising strategy to be further
exploited in the future. As Smac mimetics have recently entered phase 1
clinical trials [28], it is a timely question to develop combination pro-
tocols with these compounds to exploit synergistic drug actions. To this
end, combinations with conventional chemotherapeutic agents offer
the advantage that they might rapidly be transferred into clinical prac-
tice. In conclusion, the combination of the Smac mimetic BV6 with
gemcitabine presents a promising strategy for apoptosis-targeted thera-
pies of pancreatic cancer, which warrants further investigation.
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Figure W1. Structure of BV6. The structure of BV6 is shown
according to Varfolomeev et al. [10].
Figure W2. Dose-response and kinetic analysis. Panc1 (left panels) and MiaPaCa2 (right panels) cells were treated with indicated con-
centrations of BV6 for 72 hours (A) or with indicated concentrations of gemcitabine in the presence (black bars) or absence (white bars)
of 2 μM BV6 for 24 hours (B). Cell viability was assessed by MTT assay and is calculated as percentage of untreated cells. Means ± SEM
of three independent experiments performed in triplicate are shown.
Figure W3. Effect of BV6 on expression of IAP proteins. Panc1
(upper panel) and MiaPaCa2 (lower panel) cells were treated with
100 nM (Panc1) or 66 nM (MiaPaCa2) gemcitabine and/or 2 μM
BV6 for indicated time points. The expression of cIAP1, cIAP2,
and XIAP was assessed by Western blot analysis. GAPDH served
as loading control. One representative Western blot of two inde-
pendent experiments is shown.
Figure W4. Effect of BV6 on the cell cycle. Panc1 cells were treated
with 2 μM BV6 and/or 100 nM gemcitabine for 72 hours. Cell cycle
profiles were assessed by propidium iodide staining of permeabilized
cells and flow cytometry gating on alive cells. Percentages of cells in
G1, G2/M, and S phases of the cell cycle are shown as mean ± SEM
of three independent experiments.
Figure W5. BV6- and gemcitabine-induced NF-κB activation. Panc1
cells were treated for 1 hour with 10 ng/ml TNFα. NF-κB activation
was determined by EMSA. (A) Nuclear protein extracts prepared
from unstimulated or TNFα-stimulated cells were incubated with
labeled NF-κB oligonucleotides presenting consensus NF-κB
sequence (NF-κB) or mutated NF-κB sequence (MutNF-κB). (B) Cold
competition of EMSA assaywas performed using an excess (250 fmol)
of unlabeled NF-κB oligonucleotides (NF-κB cold).
Figure W6. Effect of IκBα-SR on BV6- and gemcitabine-induced
NF-κB activation. Panc1 cells stably transduced with a vector con-
taining IκBα-SR (IκBα-SR) or empty vector control (Co) were treated
for 4 hours with 2 μM BV6 and/or 100 nM gemcitabine or for 1 hour
with 10 ng/ml TNFα. NF-κB activation was determined by EMSA.
